Remedium Capital Partners LLC Acquires 13,247 Shares of Oruka Therapeutics, Inc. $ORKA

Remedium Capital Partners LLC grew its holdings in shares of Oruka Therapeutics, Inc. (NASDAQ:ORKA) by 0.9% in the 1st quarter, HoldingsChannel.com reports. The firm owned 1,565,661 shares of the company’s stock after purchasing an additional 13,247 shares during the quarter. Oruka Therapeutics comprises approximately 26.8% of Remedium Capital Partners LLC’s portfolio, making the stock its biggest position. Remedium Capital Partners LLC’s holdings in Oruka Therapeutics were worth $76,796,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in ORKA. Royal Bank of Canada increased its position in Oruka Therapeutics by 178.5% during the 1st quarter. Royal Bank of Canada now owns 3,172 shares of the company’s stock valued at $155,000 after buying an additional 2,033 shares in the last quarter. Rock Springs Capital Management LP acquired a new stake in Oruka Therapeutics in the first quarter worth about $202,000. The Manufacturers Life Insurance Company boosted its holdings in Oruka Therapeutics by 18.3% in the first quarter. The Manufacturers Life Insurance Company now owns 72,563 shares of the company’s stock worth $3,559,000 after acquiring an additional 11,205 shares in the last quarter. Quantinno Capital Management LP purchased a new stake in shares of Oruka Therapeutics during the first quarter worth about $254,000. Finally, Atika Capital Management LLC purchased a new stake in shares of Oruka Therapeutics during the first quarter worth about $11,277,000. Institutional investors and hedge funds own 56.44% of the company’s stock.

Oruka Therapeutics Price Performance

ORKA opened at $97.86 on Friday. The firm has a fifty day moving average price of $78.01 and a 200 day moving average price of $57.50. Oruka Therapeutics, Inc. has a 1 year low of $12.84 and a 1 year high of $98.44. The stock has a market cap of $5.90 billion, a P/E ratio of -50.44 and a beta of -0.35.

Oruka Therapeutics (NASDAQ:ORKA) last released its quarterly earnings results on Wednesday, May 13th. The company reported ($0.48) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.04. Equities analysts expect that Oruka Therapeutics, Inc. will post -2.06 EPS for the current year.

Insider Activity

In related news, Director Carl Dambkowski sold 12,583 shares of Oruka Therapeutics stock in a transaction dated Friday, June 12th. The stock was sold at an average price of $70.11, for a total value of $882,194.13. Following the completion of the transaction, the director owned 38,743 shares in the company, valued at $2,716,271.73. The trade was a 24.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,947 shares of the company’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $69.28, for a total value of $550,568.16. Following the completion of the transaction, the insider directly owned 32,718 shares of the company’s stock, valued at $2,266,703.04. The trade was a 19.54% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 188,406 shares of company stock valued at $12,019,683. Insiders own 23.49% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on ORKA. Wedbush set a $165.00 price objective on shares of Oruka Therapeutics in a report on Monday, April 27th. Barclays boosted their target price on shares of Oruka Therapeutics from $78.00 to $160.00 and gave the stock an “overweight” rating in a research report on Monday, April 27th. Piper Sandler restated an “overweight” rating and set a $180.00 price target on shares of Oruka Therapeutics in a research note on Tuesday, June 2nd. HC Wainwright reaffirmed a “buy” rating and issued a $120.00 price target on shares of Oruka Therapeutics in a report on Tuesday, June 23rd. Finally, BTIG Research reiterated a “buy” rating and set a $151.00 price objective on shares of Oruka Therapeutics in a research note on Monday, July 13th. Ten equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $134.30.

Oruka Therapeutics Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.